Company Development
May 23 2022

AND017 Cancer Related Anemia (CRA) - Phase II study NMPA IND approval

Nov 19 2021

AND019-Phase I study  NMPA IND approval

Oct 1 2021

AND019 – Phase I study FDA IND approval

Jul 2021

AND017 – Phase II study China central IRB approval

Jan 14 2021

AND017 – Phase II study FDA IND approval

Aug 2020

AND017 – China Phase I study complete

Aug 2020

Ground broken on a 200,000 square foot administrative office space and manufacturing facility in Hangzhou

Feb 2020

AND017 – Australia Phase I study complete

Nov 2019

"Innovative Entrepreneurship Team of Zhejiang Province" award

Oct 2019

Nobel Prize of Physiology or Med awarded to the MoA of AND017

Sep 2019

Decheng Capital invested exclusively on Kind

May 2019

AND019 – Initiation of IND enabling study

Apr 2019

AND017 – China Phase I study IND approval

Jul 2018

12.5 million non-dilutive grant awarded by Yuhang Industrial Fund

Nov 2017

AND017 – Patent filed in China


R&D Initiation

July 15, 2014

Founded at Yuhang District, Hangzhou